France-based mid-market and growth investor Eurazeo is joining Excelya, a European CRO, as a lead investor alongside its management team to support the group in continuing its development and pursuit of external growth ambitions.<\/p>\n
Founded in 2014 by Fran\u00e7ois Moisson<\/a> and Fr\u00e9d\u00e9ric Paqueville<\/a>, Excelya has a comprehensive service platform covering all functions required to position itself as a full-service CRO.<\/p>\n \u201cTogether, we will accelerate our growth, strengthen our presence in Europe, and continue to innovate to address the major challenges of clinical research,\u201d said Moisson, CEO of Excelya.<\/p>\n Eurazeo\u2019s investment, led by the Flex Financing team, aims to accelerate Excelya\u2019s European expansion, notably through targeted external growth. The group aspires to become the European leader in clinical research. It also supports a management transition marked by Paqueville\u2019s decision to step back from his operational role in favour of key managers working alongside Moisson.<\/p>\n \u201cThis investment in Excelya reflects our commitment to supporting European champions in high-impact sectors,\u201d said Val\u00e9rie Ducourty<\/a>, managing director Eurazeo \u2013 Flex Financing.<\/p>\n The financing of the transaction is supplemented by bank debt coordinated by Banque Populaire Val de France and Banque Populaire Rives de Paris, with the participation of BNP Paribas, Cr\u00e9dit Lyonnais, and Soci\u00e9t\u00e9 G\u00e9n\u00e9rale.<\/p>\n